细胞毒性
小分子
化学
癌症研究
机制(生物学)
作用机理
药理学
体外
医学
生物化学
认识论
哲学
作者
Bryan Oronsky,Xiaoning Guo,Xiaohui Wang,Pedro Cabrales,David J. Sher,Lou Cannizzo,Bob Wardle,Nacer D. Abrouk,Michelle Lybeck,Scott Caroen,Arnold L. Oronsky,Tony Reid
标识
DOI:10.1021/acs.jmedchem.1c00599
摘要
After extensive screening of aerospace compounds in an effort to source a novel anticancer agent, RRx-001, a first-in-class dinitroazetidine small molecule, was selected for advancement into preclinical and clinical development. RRx-001 is a minimally toxic small molecule with a distinct chemical structure and mechanism of action. The paradox of RRx-001 is that it mediates both antitumor cytotoxicity and normal tissue protection. The question of exactly how RRx-001 does this, and by means of what mechanism(s), depending on the route of delivery, intravenous or intratumoral, are explored. RRx-001 is currently in phase 2 and 3 clinical trials for the treatment of multiple solid tumor malignancies and as a supportive care drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI